BioCentury
ARTICLE | Clinical News

BAN2401 slows AD progression at 18 months

July 6, 2018 3:32 AM UTC

Biogen Inc. (NASDAQ:BIIB) gained $58.67 (20%) to $357.48 on Friday, adding about $12.3 billion in market cap, on new data for its Alzheimer's disease candidate BAN2401. Biogen and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary endpoint data late Thursday showing that the highest dose of BAN2401 significantly slowed disease progression and reduced beta amyloid at 18 months in the Phase II Study 201 to treat AD. Eisai added ¥1,500 (19%) to ¥9,206 on the news.

The trial missed its primary endpoint late last year; however, the partners said they are evaluating next steps for the compound and believe the new data "provide compelling evidence to further support amyloid hypothesis as a therapeutic target."...

BCIQ Company Profiles

Biogen Inc.

Eisai Co. Ltd.

BCIQ Target Profiles

Beta amyloid